Why New Alzheimers Drugs Make Brains Bleed is an active area of clinical research and therapeutic development covered by The Life Science Feed. Our editorial team tracks the latest clinical trials, treatment guidelines, regulatory updates, and scientific advances relevant to Why New Alzheimers Drugs Make Brains Bleed. Browse the latest articles below for in-depth analysis and evidence-based clinical insights.
Ponatinib: Efficacy vs. vascular risk, 10 years on
Ten years of real-world data confirm ponatinib's efficacy in CML and Ph+ ALL, but highlight persistent vascular occlusive event risks despite risk-management measures.
Part-Time Pay: Can Doctors Really Work Less and Thrive?
Many physicians are exploring part-time work arrangements to improve work-life balance, challenging traditional full-time expectations in medicine.
A Simpler Score for Coronary Calcium: Does it Help Predict Risk?
A simplified risk score may predict coronary artery calcium on CTA, potentially streamlining risk assessment for cardiovascular disease.
Isatuximab quadruplet deepens myeloma response, but for how long?
Isatuximab, bortezomib, lenalidomide, and dexamethasone quadruplet therapy achieved higher rates of MRD negativity and prolonged time to progression in transplant-ineligible multiple myeloma.
Can circulating metabolites clear senescent cells in TMJ-OA?
Autologous circulating extracellular vesicles (C-EVs) significantly enhanced condylar bone regeneration and alleviated symptoms in TMJ-OA patients, targeting senescent chondrocytes.
Cyclobenzaprine targets fibromyalgia pain by improving sleep
Bedtime sublingual cyclobenzaprine 5.6 mg significantly reduced daily pain in fibromyalgia patients by targeting nonrestorative sleep, a Phase 3 trial showed.
Lebrikizumab maintains atopic dermatitis remission for months off-therapy
Lebrikizumab monotherapy sustained deep remission in atopic dermatitis patients for up to 38 weeks after treatment cessation.
TNF emerges as a key node in autoimmune hepatitis, trial shows
An integrative omics approach identified TNF as a central pathogenic driver in autoimmune hepatitis, with a phase IIa trial validating TNF inhibition.
Iptacopan's 24-month IgA nephropathy data: a new standard of care?
Iptacopan significantly reduced proteinuria by 38.3% over 24 months in IgA nephropathy patients, offering a new therapeutic option.
• Aug 28 – 31ERS 2026 • Barcelona, ES 
• Sep 5 – 9EASD 2026 • Milan, IT 
• Sep 28 – Oct 2UEG Week 2026 • Vienna, AT 
• Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA 
• Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US 
• Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12ESC 2026 • Munich, DE • Aug 28 – 31ERS 2026 • Barcelona, ES • Sep 5 – 9EASD 2026 • Milan, IT • Sep 28 – Oct 2UEG Week 2026 • Vienna, AT • Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US • Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12